It is of particular interest that, in our study, the presence of poor prognostic cytogenetic abnormalities and of additional gene mutations (myeloid genes, MDS-related genes and KRAS/NRAS) had no impact on outcomes (EFS and OS). The gene discussed is KRAS; the disease is myelodysplastic syndrome.